EXEL (EXEL) Stock Price & Analysis
EXEL (EXEL) fell 0.20% to USD 59.01 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.
EXEL last closed at USD 59.01; the session ranged USD 58.46–59.26 on volume of 1,580,988 shares. Market capitalization is —, with a 52-week range of USD 33.76–59.72 (NMS). Source: Nexqual, September 8, 2026 at 04:59 UTC.
Key Statistics (as of September 8, 2026 at 04:59 UTC)
| Price | USD 59.01 |
|---|---|
| Change | ▼ 0.20% (down) |
| Previous Close | USD 59.01 |
| Open | USD 59.01 |
| Day Range | USD 58.46 – 59.26 |
| 52-Week Range | USD 33.76 – 59.72 |
| Volume | 1,580,988 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (EXEL)
Nexqual's technical model rates EXEL "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 04:59 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.79 (neutral) |
| vs SMA50 | Above (USD 55.05) |
| MACD | 1.1 (positive) |
Earnings (EXEL)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 0.91 |
| Revenue Estimate | $651.67M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.91 vs est 0.87 ▲ beat |
| 2026-03-31 | USD 0.87 vs est 0.76 ▲ beat |
| 2025-12-31 | USD 0.94 vs est 0.81 ▲ beat |
| 2025-09-30 | USD 0.78 vs est 0.67 ▲ beat |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Financials & Fundamentals (EXEL)
| Total Revenue | $2.44B |
|---|---|
| Revenue Growth (YoY) | +10.60% |
| Gross Margin | +96.48% |
| Operating Margin | +39.51% |
| Profit Margin | +35.33% |
| ROE | +44.39% |
| Debt / Equity | 9 |
| Current Ratio | 3.46 |
| Total Cash | $839.39M |
| Total Debt | $165.93M |
| Free Cash Flow | $739.72M |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Ownership (EXEL)
| Insider Ownership | +1.85% |
|---|---|
| Institutional Ownership | +107.08% |
| Shares Outstanding | 247.78M |
| Float | 213.60M |
| Short % of Float | +15.46% |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
From EXEL's Latest SEC 10-K Filing (filed 2026-02-10)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 126.75 | ▼ 1.61% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 66.53 | ▼ 0.66% |
| ACAD | ACADIA Pharmaceuticals Inc. | USD 28.02 | ▼ 3.15% |
| NBIX | Neurocrine Biosciences, Inc. | USD 155.64 | ▼ 1.36% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 546.12 | ▼ 1.91% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.